SCHEMBL3377193

SCHEMBL3377193

O=C(c1cccc(NCc2ccccc2)c1)N1CCN(CC2CCCCC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.53
LMNA P02545 4/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
MEN1 O00255 1/20 0.51
TSHR P16473 1/20 0.51
MAPK1 P28482 1/20 0.51
KMT2A Q03164 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PARP1 P09874 1/20 0.51
ALDH1A1 P00352 3/20 0.49
PKM P14618 1/20 0.48
RAB9A P51151 1/20 0.48
KDM4E B2RXH2 1/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
TP53BP1 Q12888 1/20 0.46
L3MBTL3 Q96JM7 1/20 0.46
ADRB2 P07550 1/20 0.45
SLC6A7 Q99884 1/20 0.45
UBE2M P61081 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3276253 0.88 NAMPT (0.64) NAMPTLMNAL3MBTL1MEN1MAPK1
SCHEMBL3377188 0.85 LMNA (0.54) NAMPTLMNAL3MBTL1MEN1TSHR
SCHEMBL3276251 0.80 NAMPT (0.59) NAMPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL3379832 0.79 PARP1 (0.53) NAMPTLMNAL3MBTL1MEN1TSHR
SCHEMBL3379277 0.78 ALDH1A1 (0.60) L3MBTL1TSHRMAPK1SMN1; SMN2PARP1
SCHEMBL911349 0.78 MGLL (0.53) LMNAL3MBTL1MEN1TSHRMAPK1
SCHEMBL10293610 0.75 ALDH1A1 (0.69) NAMPTLMNAL3MBTL1MEN1TSHR
SCHEMBL1240937 0.75 KDM1A (0.53) L3MBTL1MEN1TSHRKMT2ASMN1; SMN2
SCHEMBL3377142 0.74 ALDH1A1 (0.68) LMNAMEN1TSHRMAPK1KMT2A
SCHEMBL7024706 0.74 TPSAB1 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP claimed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221337-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 NAMPT 2799/4885LMNA 1619/4885L3MBTL1 1040/4885
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 NAMPT 2896/4885LMNA 2145/4885L3MBTL1 3199/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 NAMPT 2799/4885LMNA 1619/4885L3MBTL1 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.